Amgen's Imlygic gets EU committee backing; Merck touts Keytruda survival data in NSCLC;

> Amgen ($AMGN) nabbed European backing for a first-in-class cancer treatment, Imlygic, that uses a virus to deliver immunotherapy; the drug is on its way to FDA approval in the U.S. Report

> Merck & Co. ($MRK) touted top-line data showing that its immuno-oncology drug Keytruda helped certain patients with non-small-cell lung cancer live longer. Release

> GlaxoSmithKline ($GSK) won European backing to expand approval of Volibris, a treatment for pulmonary arterial hypertension, to use in combination with other meds. Report

> Novartis' ($NVS) psoriasis med Cosentyx got a thumbs up from Europe's drug approval committee for new uses in ankylosing spondylitis and psoriatic arthritis. Report

> Rare disease specialist Alexion Pharmaceuticals ($ALXN) nabbed an FDA clearance for Strensiq, which treats hypophosphatasia, a genetic disorder. Release | Report

And Finally... A new report linked some types of cancer with consumption of processed meat such as bacon and hot dogs. Report

Suggested Articles

Now that Teva's Ajovy has an autoinjector FDA approval to match its rivals, can the drug actually score the 25% market share execs are hoping for?

Social media mavens do it for the gram, but the FDA wants know whether consumers give a care about paid endorsements.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.